Back to the Canine Home Page
Pfizer Safety Study on Rimadyl
The following "Key Points" are quoted from Pfizer's web site page dealing with the safety of Rimadyl use with dogs. To view the entire report go to http://www.pfizer.com/ah/rimadyl/tbull.html
Key Points
- Since it was introduced in January 1997, Rimadyl has been prescribed for more than 2.5 million canine patients (see Note 2 in Study).
- Rimadyl effectively relieves the pain and inflammation associated with osteoarthritis, and is proven to be safe for both first-time treatment and long-term use.
- The reported rate of possible adverse reactions associated with Rimadyl is relatively low, approximately 0.18%, or less that 2/10ths of 1% of all dogs treated in 1998. Rimadyl intolerance most frequently affects the gastrointestinal tract or the liver, occurrence of which may happen without preemptive clinical signs.
- The Rimadyl product insert has been reformatted with consumer-friendly language under the heading Information for Dog Owners. Modeled after human prescription pharmaceutical labels, this section provides details for responsible usage, so that Rimadyl may be administered with greater confidence.
- A study by Allyn et al(see Note 3 in Study) found administration of cvarprofen, etodolac and placebo to healthy dogs each resulted in significantly less gastreduodenal lesion development (P greater than 0.05) than in dogs receiving aspirin.
- Buccal mucosal bleeding time was not affected by oral administration of Rimadyl to dogs (n=5) either after single dosage or following one week of continuous administration as reported by Clemmons et al, (see Note 4 in Study).
- In a study by Ko et al, carprofen together with isoflurance anesthesia did not appear to adversely affect renal function in normal dogs maintained at normal blood pressures (see Note 5 of Study).
Rescue Links
E-mail us. We'd love to hear your comments and suggestions!
